In two doubleblind, placebocontrolled studies in adults and adolescents with HDMassociated AR, 300IR HDM tablets significantly reduced mean average adjusted symptom scores (AASS) compared with placebo.2,3Although local allergic reactions occurred more frequently with active treatment than with placebo, the favorable safety profile of 300IR HDM tablets was confirmed.2,3In addition, the effectiveness of one year of treatment with 300IR HDM tablets was maintained for a subsequent year after ceasing treatment.2In Japan, HDM tablets were approved in March 2015 for allergen immunotherapy for AR due to house dust mites in adults and adolescents 12years of age (ActairSublingual Tablets 100 Units [IR] and 300 Units [IR] for HDM, Stallergenes Greer). AEs were oral pruritus, mouth edema, throat irritation, and ear pruritus. One patient experienced serious pseudocroup (subglottic laryngitis) that recovered. There were no deaths CCG-1423 or anaphylaxis requiring the use of injectable adrenaline. == Conclusions Rabbit polyclonal to EGFLAM == The HDM tablet significantly improved symptoms of HDMinduced perennial AR and was associated with a significant immunological response. The safety profile in pediatric patients was consistent with that in adults, with no new safety concerns. Keywords:allergens: inhalative allergens, rhinitis: allergic, rhinitis: clinical trials, rhinitis: specific immunotherapy, SIT: SLIT == 1. INTRODUCTION == Allergic rhinitis (AR) is a type I allergic disease characterized by repetitive sneezing, watery rhinorrhea, pruritus, and nasal blockage. One common causative antigen is the house dust mite (HDM), for example,Dermatophagoides pteronyssinusandDermatophagoides farinaespecies.1Allergenic reactions in HDM allergy are related to the adaptive immune response, which depends on immunoglobulin E (IgE),1and allergen immunotherapy involves administration of a specific allergen to provide protection against allergic symptoms and inflammatory reactions in patients with IgEmediated allergy.1 A sublingual tablet containing standardized allergen extracts fromD. pteronyssinusandD. farinaein a total allergenic activity ratio (expressed as index of reactivity [IR]) of 1 1:1 has been developed.2,3Research has shown that the 300IR HDM tablet is effective and well tolerated in adult and adolescent patients aged 12 years and older with AR. In two doubleblind, placebocontrolled studies in adults and adolescents with HDMassociated AR, 300IR HDM tablets significantly reduced mean average adjusted symptom scores (AASS) compared with placebo.2,3Although local allergic reactions occurred more frequently with active treatment than with placebo, the favorable safety CCG-1423 profile of 300IR HDM tablets was confirmed.2,3In addition, the effectiveness of one year of treatment with 300IR HDM tablets was maintained for a subsequent year after ceasing treatment.2In Japan, HDM tablets were approved in March 2015 for allergen immunotherapy for AR due to house dust mites in adults and adolescents 12 years of age (ActairSublingual Tablets 100 Units [IR] and 300 Units [IR] for HDM, Stallergenes Greer). In addition, HDM sublingual immunotherapy was added to the 2017 Japanese1and the 2015 US4AR guidelines, leading to its recognition as a treatment option for CCG-1423 AR. According to a survey in 2002, the prevalence of AR in elementary students across 11 prefectures in western Japan was 20.5%.5Because of the common underlying cellular processes, AR in children is a risk factor for subsequent development of allergic airways diseases, including asthma.6Allergen immunotherapy provides protection against allergic symptoms that is not limited to AR7and may prevent additional allergies and asthma from developing.6Therefore, it CCG-1423 is important to start allergen immunotherapy for AR in young children.6However, the efficacy, safety, and immunological response of HDM tablets in pediatric patients have not yet been demonstrated. The aim of this doubleblind, randomized, placebocontrolled study was to assess the efficacy, safety, and immunological response of standardized HDM allergen extract tablets in pediatric (5 and 16 years old) patients with perennial AR. == 2. METHODS == This multicenter, doubleblind, randomized, placebocontrolled study was conducted at 51 medical institutions throughout Japan between October 2015 and December 2016. The protocol, informed assent form, and informed consent form/written information were approved by the ethics committee of Shionogi & Co., Ltd. and the CCG-1423 institutional review board of each study site, and the study was conducted in compliance.